Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2326 to 2340 of 8917 results

  1. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria [TSID11832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Semaglutide for treating obesity-related heart failure with preserved ejection fraction [TSID11788]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. NPJ5008 for treating malignant hyperthermia [TSID11829]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Natural Cycles for monitoring fertility

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation